Safety and efficacy of the immunotherapy IMP321 in combination (adjunctive) with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic BC are under investigation in an ongoing phase 2 clinical trial (NCT02614833). Here, NR4A1 is linked to breast cancer.